|
| |
UCB S.AUCB is a leading global biopharmaceutical company dedicated to the research, development and commercialisation of innovative pharmaceutical and biotechnology products in the fields of central nervous system disorders, allergy/respiratory diseases, immune and inflammatory disorders and oncology - UCB focuses on securing a leading position in severe disease categories.VisionTo build a global biopharmaceutical leader, based on unique blending of innovation, entrepreneurship and proven experience bringing to specialists first, new medicines to treat patients suffering from severe diseases.ValuesPassion and PerformanceWe are passionate about what we do and about UCB's performance.
| Contact Details: |
| Allée de la Recherche, 60 |
| Brussels |
| |
| 1070 |
| Belgium |
| Tel: | 32/2/559.99.99 |
| Fax: | 32/2/559.99.00 |
| Email: | contactucb@UCB-Group.com |
| WWW: | www.ucb-group.com/

|
| |
Recent Publications by UCB S.A: |  |
Visualization of SV2A conformations in situ by the use of Protein Tomography.
The synaptic vesicle protein 2A (SV2A), the brain-binding site of the... | 12th August, 2008
| Department of Molecular and Cellular Sciences, UCB S.A., Granta Park,
| Biochem Biophys Res Commun. 2008 Aug 7.
DOI Direct Link |
2,6-Quinolinyl derivatives as potent VLA-4 antagonists.
A new series of 2,6-quinolinyl derivatives was prepared leading to potent... | 25th April, 2007
| UCB S.A., R&D, Chemin du Foriest, B-1420 Braine-l'Alleud, Belgium.
| Bioorg Med Chem Lett. 2007 Jan 1;17(1):142-6. Epub 2006 Oct 10.
DOI Direct Link |
Arylsulfonamides as a new class of cannabinoid CB1 receptor ligands: identification of a lead and initial SAR studies.
High-throughput screening of the UCB sample collection identified the... | 25th April, 2007
| CNS Molecular and Cellular Biology, Centre for CNS Innovation, UCB S.A.,
| Bioorg Med Chem Lett. 2007 Jan 1;17(1):272-7. Epub 2006 Oct 5.
DOI Direct Link |
The connexin 36 blockers quinine, quinidine and mefloquine inhibit cortical spreading depression in a rat neocortical slice model in vitro.
A protocol for inducing cortical spreading depression (SD) on rat... | 3rd February, 2007
| UCB S.A., CNS Research, B-1420 Braine-l'Alleud, Belgium.
| Brain Res Bull. 2006 Dec 11;71(1-3):23-8. Epub 2006 Aug 11.
DOI Direct Link |
Binding characteristics of levetiracetam to synaptic vesicle protein 2A (SV2A) in human brain and in CHO cells expressing the human recombinant protein.
A specific binding site for the antiepileptic drug levetiracetam... | 26th July, 2006
| UCB S.A., CNS Research, Chemin du Foriest, 1420 Braine L'Alleud, Belgium.
| Eur J Pharmacol. 2006 Apr 24;536(1-2):102-8. Epub 2006 Mar 10.
DOI Direct Link |
→View more UCB S.A research publications. |
BioPortfolio Ltd provides targeted e-mail address lists for the life science sector - we can enable you to contact around 16 individuals from UCB S.A using this service. Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 145 times since April 2007, the link to the organisation's website has been followed 23 times Search for more companies in Brussels Search for more companies in This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for UCB S.A |